{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T19:02:24Z","timestamp":1767985344925,"version":"3.49.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2025,5,25]],"date-time":"2025-05-25T00:00:00Z","timestamp":1748131200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,5,25]],"date-time":"2025-05-25T00:00:00Z","timestamp":1748131200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Urol Nephrol"],"DOI":"10.1007\/s11255-025-04577-0","type":"journal-article","created":{"date-parts":[[2025,5,25]],"date-time":"2025-05-25T13:07:42Z","timestamp":1748178462000},"page":"4077-4086","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Predictive clinical characteristics for adverse pathological outcomes in intermediate- and high-risk prostate cancer during biopsy"],"prefix":"10.1007","volume":"57","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5215-8729","authenticated-orcid":false,"given":"Miroslav","family":"Stojadinovic","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1609-6313","authenticated-orcid":false,"given":"Nebojsa","family":"Jurisevic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1332-6961","authenticated-orcid":false,"given":"Milorad","family":"Stojadinovic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1519-8828","authenticated-orcid":false,"given":"Slobodan","family":"Jankovic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,5,25]]},"reference":[{"issue":"6","key":"4577_CR1","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1016\/j.euo.2021.09.006","volume":"4","author":"G Gandaglia","year":"2021","unstructured":"Gandaglia G, Leni R, Bray F et al (2021) Epidemiology and prevention of prostate cancer. EurUrol Oncol 4(6):877\u2013892. https:\/\/doi.org\/10.1016\/j.euo.2021.09.006","journal-title":"EurUrol Oncol"},{"issue":"3","key":"4577_CR2","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2020","unstructured":"Sung H, Ferlay J, Siegel RL et al (2020) Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 Countries. CA Cancer J Clin 71(3):209\u2013249. https:\/\/doi.org\/10.3322\/caac.21660","journal-title":"CA Cancer J Clin"},{"key":"4577_CR3","doi-asserted-by":"publisher","first-page":"1334845","DOI":"10.3389\/fonc.2024.1334845","volume":"14","author":"MT Bourlon","year":"2024","unstructured":"Bourlon MT, Urbina-Ramirez S, Verduzco-Aguirre HC et al (2024) Differences in the expression of the phosphatase PTP-1B in patients with localized prostate cancer with and without adverse pathological features. Front Oncol 14:1334845. https:\/\/doi.org\/10.3389\/fonc.2024.1334845","journal-title":"Front Oncol"},{"issue":"1","key":"4577_CR4","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1186\/s12885-023-11771-9","volume":"24","author":"JS Enke","year":"2024","unstructured":"Enke JS, Gro\u00df M, Grosser B et al (2024) SARIFA as a new histopathological biomarker is associated with adverse clinicopathological characteristics, tumor-promoting fatty-acid metabolism, and might predict a metastatic pattern in pT3a prostate cancer. BMC Cancer 24(1):65. https:\/\/doi.org\/10.1186\/s12885-023-11771-9","journal-title":"BMC Cancer"},{"issue":"2","key":"4577_CR5","doi-asserted-by":"publisher","first-page":"170","DOI":"10.4103\/ijc.IJC_516_20","volume":"59","author":"S Jain","year":"2022","unstructured":"Jain S, Mallick I, Tamhankar AS, Gautam G (2022) Adjuvant versus early Salvage radiation therapy for prostate cancer with adverse pathological features on radical prostatectomy\u2014do we finally have an answer? Indian J Cancer 59(2):170\u2013177. https:\/\/doi.org\/10.4103\/ijc.IJC_516_20","journal-title":"Indian J Cancer"},{"issue":"11","key":"4577_CR6","doi-asserted-by":"publisher","first-page":"1793","DOI":"10.1001\/jamaoncol.2020.2832","volume":"6","author":"S Sachdev","year":"2020","unstructured":"Sachdev S, Carroll P, Sandler H et al (2020) Assessment of postprostatectomy radiotherapy as adjuvant or salvage therapy in patients with prostate cancer: a systematic review. JAMA Oncol 6(11):1793\u20131800. https:\/\/doi.org\/10.1001\/jamaoncol.2020.2832","journal-title":"JAMA Oncol"},{"issue":"1","key":"4577_CR7","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.euf.2023.08.010","volume":"10","author":"RM Bernardino","year":"2024","unstructured":"Bernardino RM, Sayyid RK, Lajkosz K et al (2024) Limitations of prostate biopsy in detection of cribriform and intraductal prostate cancer. EurUrol Focus 10(1):146\u2013153. https:\/\/doi.org\/10.1016\/j.euf.2023.08.010","journal-title":"EurUrol Focus"},{"issue":"3","key":"4577_CR8","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1002\/pros.24279","volume":"82","author":"C Ma","year":"2022","unstructured":"Ma C, Downes M, Jain R et al (2022) Prevalence of adverse pathology features in grade group 2 prostatectomy specimens with syn- or metachronous metastatic disease. Prostate 82(3):345\u2013351. https:\/\/doi.org\/10.1002\/pros.24279","journal-title":"Prostate"},{"issue":"6","key":"4577_CR9","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1016\/j.eururo.2019.09.005","volume":"77","author":"G Gandaglia","year":"2020","unstructured":"Gandaglia G, Ploussard G, Valerio M et al (2020) The key combined value of multiparametric magnetic resonance imaging, and magnetic resonance imaging-targeted and concomitant systematic biopsies for the prediction of adverse pathological features in prostate cancer patients undergoing radical prostatectomy. Eur Urol 77(6):733\u2013741. https:\/\/doi.org\/10.1016\/j.eururo.2019.09.005","journal-title":"Eur Urol"},{"issue":"6","key":"4577_CR10","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.acuroe.2022.02.004","volume":"46","author":"N Karsiyakali","year":"2022","unstructured":"Karsiyakali N, Bulent Ozgen M, Ozveren B et al (2022) The association between perineural invasion in mpMRI-targeted and\/or systematic prostate biopsy and adverse pathological outcomes in robot-assisted radical prostatectomy. ActasUrol Esp (Engl Ed) 46(6):377\u2013384. https:\/\/doi.org\/10.1016\/j.acuroe.2022.02.004","journal-title":"ActasUrol Esp (Engl Ed)"},{"issue":"15","key":"4577_CR11","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.70085","volume":"13","author":"R Shi","year":"2024","unstructured":"Shi R, Huang D, Yan J et al (2024) phi and phiD predict adverse pathological features after radical prostatectomy for prostate cancer in Chinese population. Cancer Med 13(15):e70085. https:\/\/doi.org\/10.1002\/cam4.70085","journal-title":"Cancer Med"},{"issue":"5","key":"4577_CR12","doi-asserted-by":"publisher","first-page":"479","DOI":"10.6004\/jnccn.2019.0023","volume":"17","author":"JL Mohler","year":"2019","unstructured":"Mohler JL, Antonarakis ES, Armstrong AJ et al (2019) Prostate cancer, version 2.2019, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Cancer Netw. 17(5):479\u2013505. https:\/\/doi.org\/10.6004\/jnccn.2019.0023","journal-title":"J Natl Compr Cancer Netw."},{"issue":"6","key":"4577_CR13","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1016\/j.urology.2014.02.035","volume":"83","author":"DP Ankerst","year":"2014","unstructured":"Ankerst DP, Hoefler J, Bock S et al (2014) Prostate cancer prevention trial risk calculator 2.0 for the prediction of low- vs high-grade prostate cancer. Urology 83(6):1362\u20131367. https:\/\/doi.org\/10.1016\/j.urology.2014.02.035","journal-title":"Urology"},{"issue":"2","key":"4577_CR14","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.eururo.2018.05.003","volume":"74","author":"DP Ankerst","year":"2018","unstructured":"Ankerst DP, Straubinger J, Selig K et al (2018) A contemporary prostate biopsy risk calculator based on multiple heterogeneous cohorts. Eur Urol 74(2):197\u2013203. https:\/\/doi.org\/10.1016\/j.eururo.2018.05.003","journal-title":"Eur Urol"},{"issue":"2","key":"4577_CR15","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1007\/s00345-011-0804-y","volume":"30","author":"MJ Roobol","year":"2012","unstructured":"Roobol MJ, Schr\u00f6der FH, Hugosson J et al (2012) Importance of prostate volume in the European Randomised Study of Screening for Prostate Cancer (ERSPC) risk calculators: results from the prostate biopsy collaborative group. World J Urol 30(2):149\u2013155. https:\/\/doi.org\/10.1007\/s00345-011-0804-y","journal-title":"World J Urol"},{"issue":"3","key":"4577_CR16","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1016\/j.euf.2020.05.002","volume":"7","author":"A Mortezavi","year":"2021","unstructured":"Mortezavi A, Palsdottir T, Eklund M et al (2021) Head-to-head comparison of conventional, and image- and biomarker-based prostate cancer risk calculators. EurUrol Focus 7(3):546\u2013553. https:\/\/doi.org\/10.1016\/j.euf.2020.05.002","journal-title":"EurUrol Focus"},{"key":"4577_CR17","unstructured":"Nykodym T, Kraljevic T, Wang A, Wong W (2016) Generalized linear modeling with h2o. Published by H2O. ai Inc [online]. 2016. https:\/\/docs.h2o.ai\/h2o\/latest-stable\/h2o-docs\/booklets\/GLMBooklet.pdf. Accessed 23 Apr 2023"},{"issue":"352","key":"4577_CR18","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.i6","volume":"25","author":"AJ Vickers","year":"2016","unstructured":"Vickers AJ, Van Calster B, Steyerberg EW (2016) Net benefit approaches to the evaluation of prediction models, molecular markers, and diagnostic tests. BMJ 25(352):i6. https:\/\/doi.org\/10.1136\/bmj.i6","journal-title":"BMJ"},{"issue":"9","key":"4577_CR19","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1093\/jnci\/djq099","volume":"102","author":"HG Welch","year":"2010","unstructured":"Welch HG, Black WC (2010) Overdiagnosis in cancer. J Natl Cancer Inst 102(9):605\u2013613. https:\/\/doi.org\/10.1093\/jnci\/djq099","journal-title":"J Natl Cancer Inst"},{"key":"4577_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/EDBK_279459","volume":"40","author":"RR McKay","year":"2020","unstructured":"McKay RR, Feng FY, Wang AY, Wallis CJD, Moses KA (2020) Recent advances in the management of high-risk localized prostate cancer: local therapy, systemic therapy, and biomarkers to guide treatment decisions. Am Soc Clin Oncol Educ Book 40:1\u201312. https:\/\/doi.org\/10.1200\/EDBK_279459","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"3","key":"4577_CR21","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1016\/j.juro.2015.01.126","volume":"194","author":"SE Eggener","year":"2015","unstructured":"Eggener SE, Badani K, Barocas DA et al (2015) Gleason 6 prostate cancer: translating biology into population health. J Urol 194(3):626\u2013634. https:\/\/doi.org\/10.1016\/j.juro.2015.01.126","journal-title":"J Urol"},{"issue":"9","key":"4577_CR22","doi-asserted-by":"publisher","first-page":"1414","DOI":"10.1002\/cncr.29147","volume":"121","author":"Z Klaassen","year":"2015","unstructured":"Klaassen Z, Singh AA, Howard LE et al (2015) Is clinical stage T2c prostate cancer an intermediate- or high-risk disease? Cancer 121(9):1414\u20131421. https:\/\/doi.org\/10.1002\/cncr.29147","journal-title":"Cancer"},{"issue":"3","key":"4577_CR23","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/j.clgc.2017.10.013","volume":"16","author":"DD Yang","year":"2018","unstructured":"Yang DD, Mahal BA, Muralidhar V (2018) Pathologic outcomes of Gleason 6 favorable intermediate-risk prostate cancer treated with radical prostatectomy: implications for active surveillance. Clin Genitourin Cancer 16(3):226\u2013234. https:\/\/doi.org\/10.1016\/j.clgc.2017.10.013","journal-title":"Clin Genitourin Cancer"},{"issue":"22","key":"4577_CR24","doi-asserted-by":"publisher","first-page":"2959","DOI":"10.1200\/JCO.2010.32.6371","volume":"29","author":"RK Nam","year":"2011","unstructured":"Nam RK, Kattan MW, Chin JL et al (2011) Prospective multi-institutional study evaluating the performance of prostate cancer risk calculators. J Clin Oncol 29(22):2959\u20132964. https:\/\/doi.org\/10.1200\/JCO.2010.32.6371","journal-title":"J Clin Oncol"},{"issue":"2","key":"4577_CR25","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.eururo.2020.09.042","volume":"79","author":"N Mottet","year":"2021","unstructured":"Mottet N, van den Bergh RCN, Briers E et al (2021) EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer-2020 Update. Part 1: screening, diagnosis, and local treatment with curative intent. Eur Urol 79(2):243\u2013262. https:\/\/doi.org\/10.1016\/j.eururo.2020.09.042","journal-title":"Eur Urol"},{"key":"4577_CR26","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.euros.2022.08.006","volume":"44","author":"J Andersson","year":"2022","unstructured":"Andersson J, Palsdottir T, Lantz A et al (2022) Digital rectal examination in Stockholm3 biomarker-based prostate cancer screening. EurUrol Open Sci 44:69\u201375. https:\/\/doi.org\/10.1016\/j.euros.2022.08.006","journal-title":"EurUrol Open Sci"},{"issue":"10","key":"4577_CR27","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1080\/03007995.2016.1198312","volume":"32","author":"T Cui","year":"2016","unstructured":"Cui T, Kovell RC, Terlecki RP (2016) Is it time to abandon the digital rectal examination? Lessons from the PLCO Cancer Screening Trial and peer-reviewed literature. Curr Med Res Opin 32(10):1663\u20131669. https:\/\/doi.org\/10.1080\/03007995.2016.1198312","journal-title":"Curr Med Res Opin"},{"issue":"10","key":"4577_CR28","doi-asserted-by":"publisher","first-page":"728.e7","DOI":"10.1016\/j.urolonc.2020.12.029","volume":"39","author":"N Omri","year":"2021","unstructured":"Omri N, Alex S, Jacob B, Ofer N (2021) The additive value of mpMRI on prostate cancer detection: comparison between patients with and without a suspicious digital rectal examination (DRE). Urol Oncol 39(10):728.e7-728.e11. https:\/\/doi.org\/10.1016\/j.urolonc.2020.12.029","journal-title":"Urol Oncol"},{"issue":"3","key":"4577_CR29","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1038\/s41391-024-00852-w","volume":"27","author":"FB Denijs","year":"2024","unstructured":"Denijs FB, van Harten MJ, Meenderink JJL et al (2024) Risk calculators for the detection of prostate cancer: a systematic review. Prostate Cancer Prostatic Dis 27(3):544\u2013557. https:\/\/doi.org\/10.1038\/s41391-024-00852-w","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"5","key":"4577_CR30","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1002\/bco2.146","volume":"3","author":"P Davik","year":"2022","unstructured":"Davik P, Remmers S, Elschot M (2022) Reducing prostate biopsies and magnetic resonance imaging with prostate cancer risk stratification. BJUI Compass 3(5):344\u2013353. https:\/\/doi.org\/10.1002\/bco2.146","journal-title":"BJUI Compass"},{"issue":"1","key":"4577_CR31","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1097\/JU.0000000000002757","volume":"208","author":"JA Eastham","year":"2022","unstructured":"Eastham JA, Auffenberg GB, Barocas DA et al (2022) Clinically localized prostate cancer: AUA\/ASTRO guideline, part I: introduction, risk assessment, staging, and risk-based management. J Urol 208(1):10\u201318. https:\/\/doi.org\/10.1097\/JU.0000000000002757","journal-title":"J Urol"},{"issue":"1","key":"4577_CR32","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.euf.2019.03.001","volume":"7","author":"S Dieffenbacher","year":"2021","unstructured":"Dieffenbacher S, Nyarangi-Dix J, Giganti F et al (2021) Standardized magnetic resonance imaging reporting using the prostate cancer radiological estimation of change in sequential evaluation criteria and magnetic resonance imaging\/transrectal ultrasound fusion with transperineal saturation biopsy to select men on active surveillance. EurUrol Focus 7(1):102\u2013110. https:\/\/doi.org\/10.1016\/j.euf.2019.03.001","journal-title":"EurUrol Focus"},{"issue":"21","key":"4577_CR33","doi-asserted-by":"publisher","first-page":"3350","DOI":"10.3390\/diagnostics13213350","volume":"13","author":"JY Chen","year":"2023","unstructured":"Chen JY, Wang PY, Liu MZ et al (2023) Biomarkers for prostate cancer: from diagnosis to treatment. Diagnostics (Basel) 13(21):3350. https:\/\/doi.org\/10.3390\/diagnostics13213350","journal-title":"Diagnostics (Basel)"},{"key":"4577_CR34","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.urology.2020.07.040","volume":"145","author":"N Lamba","year":"2020","unstructured":"Lamba N, Butler S, Mahal BA et al (2020) Three-tiered subclassification system of high-risk prostate cancer in men managed with radical prostatectomy: implications for treatment decision-making. Urology 145:197\u2013203. https:\/\/doi.org\/10.1016\/j.urology.2020.07.040","journal-title":"Urology"},{"issue":"1","key":"4577_CR35","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1186\/s12916-019-1466-7","volume":"17","author":"B Van Calster","year":"2019","unstructured":"Van Calster B, McLernon DJ, van Smeden M et al (2019) Calibration: the Achilles heel of predictive analytics. BMC Med 17(1):230. https:\/\/doi.org\/10.1186\/s12916-019-1466-7","journal-title":"BMC Med"},{"issue":"3","key":"4577_CR36","doi-asserted-by":"publisher","DOI":"10.2196\/30430","volume":"7","author":"A Bandala-Jacques","year":"2021","unstructured":"Bandala-Jacques A, Castellanos Esquivel KD et al (2021) Prostate cancer risk calculators for healthy populations: systematic review. JMIR Cancer 7(3):e30430. https:\/\/doi.org\/10.2196\/30430","journal-title":"JMIR Cancer"},{"issue":"1","key":"4577_CR37","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.clgc.2016.06.003","volume":"15","author":"TP Leit\u00e3o","year":"2017","unstructured":"Leit\u00e3o TP, Alfarelos J, Rodrigues T et al (2017) A prospective randomized trial comparing the Vienna nomogram and a ten-core prostate biopsy protocol: effect on cancer detection rate. Clin Genitourin Cancer 15(1):117\u2013121. https:\/\/doi.org\/10.1016\/j.clgc.2016.06.003","journal-title":"Clin Genitourin Cancer"}],"container-title":["International Urology and Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-025-04577-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11255-025-04577-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-025-04577-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T18:08:45Z","timestamp":1761847725000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11255-025-04577-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,25]]},"references-count":37,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4577"],"URL":"https:\/\/doi.org\/10.1007\/s11255-025-04577-0","relation":{},"ISSN":["1573-2584"],"issn-type":[{"value":"1573-2584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,25]]},"assertion":[{"value":"9 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Written informed consent was not required for this study, as the database contained only anonymous patient data with no identifying information. The research project was approved by the Ethics Committee of the Clinical Center Kragujevac on January 17, 2658. All ethical guidelines set forth in the World Medical Association's Declaration of Helsinki for medical research involving human participants were adhered to.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}